Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

ed in the morphine arm in the period 6 - 24 hours after treatment. This was the second primary endpoint and approached statistical significance (p=0.052).

Morphine formulations are the gold standard treatment for the relief of moderate to severe post-operative pain. A limitation of morphine treatment is often the unpleasant side effects experienced, of which nausea and vomiting are the most common. PONV is rated among patients as one of the most distressing after-effects of surgery and reduces their quality of life.

M6G's lower propensity to cause nausea and vomiting in the post-operative period strongly supports CeNeS' belief in the potential of M6G as a novel product for the treatment of post-operative pain with clear advantages over morphine.

3. Safety profile/adverse events

The trial confirmed that M6G's safety profile is similar to morphine. Aside from nausea and vomiting, the adverse events reported were at levels similar to those experienced by patients receiving morphine in a post-operative setting.

4. Management of PONV/use of anti-emetics

Secondary data revealed that patients receiving M6G required over 20% less anti-emetic medication over the 0-24 hour period than those in the morphine group. This shows that not only does M6G induce significantly less nausea and vomiting than morphine, but also that the post-operative anti-emetic treatment required is considerably reduced.

The potential for reduced anti-emetic drug costs combined with the reduction in medical assistance and the improved patient comfort due to lower PONV supports CeNeS' justification of a substantial price premium for M6G compared to morphine.

5. Drug consumption

It has been shown in previous studies that the dose of M6G required to provide analgesia immediately after surgery is three times that of morphine. In accordance with this, the M6G022 trial was designed such that M6G was available in a 3:1 ratio to morphine during the
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading ... it has signed a three-year single source ... supply contracting company, for MAQUET,s market-leading VASOVIEW ... products assist healthcare providers in obtaining veins ... only small incisions. This allows for faster ...
(Date:12/16/2009)... Naurex Inc., a new clinical stage ... CNS disorders based on its novel GFPA NMDA ... a Phase I clinical trial of its lead ... subjects in the study. GLYX-13, a glycine ... the NMDA receptor, is initially being developed as ...
(Date:12/16/2009)... Texas, Dec. 16 Savara, Inc., an inhalation ... the second tranche in its Series A financing round, ... ,, Funds raised in the Series A ... the NanoCluster technology. ,, "We now have the ... performance of the NanoCluster technology," said Rob Neville, CEO ...
Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 2Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression 3Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent 2Solon Manufacturing Company Acquires PurFybr Brands 3B Adds Influenza Virus Diagnostic Swabs to Product Line 12710 1Solon Manufacturing Company Acquires PurFybr Brands 3B Adds Influenza Virus Diagnostic Swabs to Product Line 12710 2Pesticide Residue Common on Kitchen Floors 49522 1Pesticide Residue Common on Kitchen Floors 49522 2Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 1Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 2Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 3Researchers observe single protein dimers wavering between two symmetrically opposed structures 8934 4
(Date:12/16/2009)... pinpoint seven that increase susceptibility to disease , , ... associated with increased susceptibility to leprosy have been ... The researchers, who analyzed more than 10,000 DNA ... China, said their discovery highlights the important role ... development of leprosy. , "Though leprosy is not ...
(Date:12/16/2009)... The omega-3 essential fatty acids commonly found ... sensory overload, according to research published by the ... to the information-processing problems found in people with ... disease; and other afflictions of the nervous system. ... Behavioral Neuroscience , provides more evidence that ...
(Date:12/16/2009)... global leader of Digital Pen and Paper technology and the ... trials, today announced that it is ranked among the Fastest ... EMEA 2009. , ... (PRWEB) December ... solutions for the capture, digitalization and management of handwritten data. ...
(Date:12/16/2009)... all-time low, government report shows, , , WEDNESDAY, Dec. 16 ... States has reached almost 78 years, a record high, ... 2007, women can expect to live to 80.4 years ... the report from the U.S. Centers for Disease Control ... expect to live longer than their parents, life expectancy ...
(Date:12/16/2009)... New research published online, December ... pistachios, and molecules present in pistachios, have ... levels of an inflammatory marker known as ... Inflammation is a complex biological response to ... and it underlies functional changes associated with ...
Breaking Medicine News(10 mins):Health News:Leprosy Genes Identified 2Health News:New study links DHA type of omega-3 to better nervous-system function 2Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News: Life Expectancy in U.S. Hits New High 2Health News: Life Expectancy in U.S. Hits New High 3Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 2Health News:New Study Reveals Pistachios Have Anti-Inflammatory Properties 3
... June 5 Soaring gas prices are,a contributing factor ... on,the poorest and most vulnerable within the global community ... situation is particularly devastating in Ethiopia, one of the ... in 2007 and again in 2008,compounded the Ethiopian situation, ...
... ) today reported preliminary total retail drug,store sales for the four-week and seventeen-week periods ended May 29,2008., ... Periods ended May 29, 2008 ... Month Year to Date (Dollars ... (4 weeks) (17 weeks), Total retail drug store sales ...
... A Closer Look at The Value of,MRIs ... of,America,s (MSAA) website, http://www.msassociation.org . This three ... offering a first-hand,account on the experience of undergoing ... well as the importance of MRIs to monitor ...
... Benchmarking is not a luxury;,it is an activity that ... a survey analysis of 30 companies and in-depth interviews,with ... benchmarking in a,difficult economy., The complete study addresses ... the goals of benchmarking studies, how companies are,demonstrating value ...
... Forum to Explore Solutions Presented by The Massachusetts ... 5 "We are greatly,concerned in this state about ... of our returning veterans, the stress, depression and ... specter of rising levels of,domestic violence and suicide. ...
... entertainment and ... more, ... fitness and figure competitors Allison,Frahn and Tina Durkin, will represent GNC at ... Centre in Atlanta., Chad, part of the World Natural Bodybuilding Federation ...
Other Medicine News:Health News:Impact of Rising Gas, Food Prices Felt Globally 2Health News:Longs Reports Preliminary May Retail Drug Store Sales 2Health News:Photos: The Multiple Sclerosis Association of America Produces a Web Video on the Importance of MRIs 2Health News:Demonstrating the Value of Benchmarking in an Uncertain Economy 2Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2Health News:Rite Aid Health and Beauty Expo to Showcase GNC Athletes 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: